

# Farrokh Dehdashti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5276615/publications.pdf>

Version: 2024-02-01

139  
papers

11,141  
citations

26626

56  
h-index

29154

104  
g-index

142  
all docs

142  
docs citations

142  
times ranked

9028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET). <i>Annals of Surgery</i> , 2004, 240, 438-450.	4.2	541
2	Lymph Node Staging by Positron Emission Tomography in Patients With Carcinoma of the Cervix. <i>Journal of Clinical Oncology</i> , 2001, 19, 3745-3749.	1.6	439
3	Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2797-2803.	1.6	377
4	Assessing tumor hypoxia in cervical cancer by positron emission tomography with <sup>60</sup> Cu-ATSM: Relationship to therapeutic response—a preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1233-1238.	0.8	324
5	FDG PET Evaluation of Mucinous Neoplasms. <i>American Journal of Roentgenology</i> , 2000, 174, 1005-1008.	2.2	300
6	The standardized uptake value for <sup>18</sup> F fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. <i>Cancer</i> , 2007, 110, 1738-1744.	4.1	271
7	Lymph Node Staging by Positron Emission Tomography in Cervical Cancer: Relationship to Prognosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 2108-2113.	1.6	262
8	Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2289.	7.4	260
9	Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. <i>Diseases of the Colon and Rectum</i> , 2000, 43, 759-767.	1.3	254
10	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 774.	7.4	252
11	Positron Emission Tomography in Limited-Stage Small-Cell Lung Cancer: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 3248-3254.	1.6	250
12	Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. <i>Annals of Surgical Oncology</i> , 1997, 4, 613-620.	1.5	248
13	Improvement in Staging of Esophageal Cancer With the Addition of Positron Emission Tomography. <i>Annals of Thoracic Surgery</i> , 1997, 64, 770-777.	1.3	234
14	Posttherapy [ <sup>18</sup> F] Fluorodeoxyglucose Positron Emission Tomography in Carcinoma of the Cervix: Response and Outcome. <i>Journal of Clinical Oncology</i> , 2004, 22, 2167-2171.	1.6	228
15	Utility of FDG-PET for Investigating Unexplained Plasma CEA Elevation in Patients With Colorectal Cancer. <i>Annals of Surgery</i> , 1998, 227, 319-323.	4.2	226
16	Assessing Tumor Hypoxia in Cervical Cancer by PET with <sup>60</sup> Cu-Labeled Diacetyl-Bis( <sup>4</sup> N-Methylthiosemicarbazone). <i>Journal of Nuclear Medicine</i> , 2008, 49, 201-205.	5.0	221
17	Prospective Study of [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4314-4320.	1.6	219
18	Positron tomographic assessment of androgen receptors in prostatic carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 344-350.	6.4	216

#	ARTICLE	IF	CITATIONS
19	11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. Journal of Nuclear Medicine, 2003, 44, 549-55.	5.0	209
20	Detection of Primary Hepatic Malignancy in Liver Transplant Candidates: Prospective Comparison of CT, MR Imaging, US, and PET. Radiology, 2003, 226, 533-542.	7.3	200
21	PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Research and Treatment, 2009, 113, 509-517.	2.5	189
22	Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiotherapy and Oncology, 2012, 102, 239-245.	0.6	183
23	18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?. Journal of Nuclear Medicine, 2006, 47, 1808-12.	5.0	183
24	An Imaging Comparison of <sup>64</sup> Cu-ATSM and <sup>60</sup> Cu-ATSM in Cancer of the Uterine Cervix. Journal of Nuclear Medicine, 2008, 49, 1177-1182.	5.0	178
25	Survival of Patients Evaluated by FDG-PET Before Hepatic Resection for Metastatic Colorectal Carcinoma: A Prospective Database Study. Annals of Surgery, 2001, 233, 293-299.	4.2	171
26	Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer, 2005, 104, 2484-2491.	4.1	168
27	Prospective Evaluation of Positron Emission Tomography for the Detection of Groin Node Metastases from Vulvar Cancer. Gynecologic Oncology, 2002, 85, 179-184.	1.4	162
28	Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecologic Oncology, 2004, 95, 546-551.	1.4	158
29	Tumor Hypoxia Detected by Positron Emission Tomography with <sup>60</sup> Cu-ATSM as a Predictor of Response and Survival in Patients Undergoing Neoadjuvant Chemoradiotherapy for Rectal Carcinoma: A Pilot Study. Diseases of the Colon and Rectum, 2008, 51, 1641-1648.	1.3	151
30	18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. Journal of Nuclear Medicine, 2011, 52, 386-392.	5.0	151
31	F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecologic Oncology, 2006, 101, 147-151.	1.4	122
32	Evaluation of <sup>111</sup> In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. Journal of Nuclear Medicine, 2003, 44, 700-7.	5.0	105
33	Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 130-134.	1.1	104
34	FDG-PET evaluation of vaginal carcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 62, 733-737.	0.8	103
35	Pelvic lymph node <sup>18</sup> F fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer, 2010, 116, 1469-1475.	4.1	103
36	[ <sup>89</sup> Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging and Biology, 2016, 18, 952-959.	2.6	103

#	ARTICLE	IF	CITATIONS
37	Posttherapy surveillance monitoring of cervical cancer by FDG-PET. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 907-913.	0.8	102
38	FDG-PET-based prognostic nomograms for locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 136-140.	1.4	96
39	Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. <i>Gynecologic Oncology</i> , 2003, 90, 572-576.	1.4	94
40	PET in breast cancer. <i>Seminars in Nuclear Medicine</i> , 1998, 28, 290-302.	4.6	92
41	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652.	2.0	92
42	Evaluation of Gynecologic Cancer with MR Imaging, <sup>18</sup> F-FDG PET/CT, and PET/MR Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 436-443.	5.0	90
43	Comparison of Molecular Markers of Hypoxia and Imaging with <sup>60</sup> Cu-ATSM in Cancer of the Uterine Cervix. <i>Molecular Imaging and Biology</i> , 2007, 9, 278-283.	2.6	88
44	Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. <i>Gynecologic Oncology</i> , 2009, 112, 104-109.	1.4	84
45	Characterizing Tumors Using Metabolic Imaging: PET Imaging of Cellular Proliferation and Steroid Receptors. <i>Neoplasia</i> , 2000, 2, 71-88.	5.3	81
46	<sup>11</sup> C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction. <i>Journal of Nuclear Medicine</i> , 2013, 54, 699-706.	5.0	81
47	FDG-PET Evaluation of Indeterminate Pancreatic Masses. <i>Journal of Computer Assisted Tomography</i> , 1996, 20, 363-369.	0.9	78
48	Assessment of Cellular Proliferation in Tumors by PET Using <sup>18</sup> F-ISO-1. <i>Journal of Nuclear Medicine</i> , 2013, 54, 350-357.	5.0	76
49	Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. <i>Gynecologic Oncology</i> , 2013, 130, 64-68.	1.4	73
50	Cervical cancer histology and tumor differentiation affect <sup>18</sup> F-fluorodeoxyglucose uptake. <i>Cancer</i> , 2009, 115, 3548-3554.	4.1	71
51	Assessment of Progesterone Receptors in Breast Carcinoma by PET with <sup>21</sup> - <sup>18</sup> F-Fluoro-16 $\beta$ ,17 $\beta$ -[1 $\alpha$ -( <i>R</i> )-(1 $\alpha$ - <sup>2</sup> -furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione. <i>Journal of Nuclear Medicine</i> , 2012, 53, 363-370.	5.0	71
52	Gold Nanoclusters Doped with <sup>64</sup> Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis. <i>ACS Nano</i> , 2016, 10, 5959-5970.	14.6	71
53	Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. <i>Gynecologic Oncology</i> , 2016, 142, 413-419.	1.4	65
54	FDG-PET Evaluation of Carcinoma of the Cervix. <i>Molecular Imaging and Biology</i> , 1999, 2, 105-109.	0.3	63

#	ARTICLE	IF	CITATIONS
55	Usefulness of Intraoperative Sonography for Revealing Hepatic Metastases from Colorectal Cancer in Patients Selected for Surgery After Undergoing FDG PET. American Journal of Roentgenology, 2002, 178, 353-358.	2.2	60
56	Evaluation of [ <sup>89</sup> Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research and Treatment, 2018, 169, 523-530.	2.5	59
57	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1088-1097.	0.8	57
58	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Gynecologic Oncology, 2020, 157, 639-643.	1.4	57
59	Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. Journal of Nuclear Medicine, 2003, 44, 192-7.	5.0	55
60	Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiotherapy and Oncology, 2010, 95, 288-291.	0.6	53
61	Neoplasms of the esophagus and stomach. Seminars in Nuclear Medicine, 2004, 34, 198-208.	4.6	52
62	Combined [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid Cancer. Annals of Surgical Oncology, 2008, 15, 286-292.	1.5	52
63	Exclusion of Malignancy in Thyroid Nodules with Indeterminate Fine Needle Aspiration Cytology After Negative <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography: Interim Analysis. World Journal of Surgery, 2010, 34, 1247-1253.	1.6	52
64	Novel Methods and Tracers for Breast Cancer Imaging. Seminars in Nuclear Medicine, 2013, 43, 324-329.	4.6	52
65	Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology, 2017, 283, 450-459.	7.3	51
66	Preclinical Development of CD38-Targeted [ <sup>89</sup> Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. Journal of Nuclear Medicine, 2018, 59, 216-222.	5.0	50
67	Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 550-562.	6.4	48
68	Comparative breast tumor imaging and comparative in vitro metabolism of <sup>16</sup> β-[ <sup>18</sup> F]Fluoroestradiol-17 <sup>β</sup> and <sup>16</sup> β-[ <sup>18</sup> f]fluoromoxestrol in isolated hepatocytes. Nuclear Medicine and Biology, 1999, 26, 123-130.	0.6	47
69	Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. British Journal of Cancer, 2018, 118, 72-78.	6.4	46
70	Clinical application of PET/MRI in oncology. Journal of Magnetic Resonance Imaging, 2016, 44, 265-276.	3.4	45
71	Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix. Journal of Magnetic Resonance Imaging, 2013, 37, 431-434.	3.4	44
72	Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 75S-80S.	5.0	43

#	ARTICLE	IF	CITATIONS
73	Phase 1 Evaluation of [ <sup>64</sup> Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. <i>Molecular Imaging and Biology</i> , 2016, 18, 446-453.	2.6	40
74	Correlation of Severity of FDG- $\tau$ PET Hypometabolism and Interictal Regional Delta Slowing in Temporal Lobe Epilepsy. <i>Epilepsia</i> , 2005, 46, 573-576.	5.1	38
75	Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2186-2194.	7.0	37
76	Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 19669-19678.	8.0	37
77	Evaluation of Hypoxia With Copper-Labeled Diacetyl-bis(N-Methylthiosemicarbazone). <i>Seminars in Nuclear Medicine</i> , 2015, 45, 177-185.	4.6	34
78	Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. <i>Nature Communications</i> , 2021, 12, 733.	12.8	33
79	PET/MRI Evaluation of Gynecologic Malignancies and Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 293-303.	4.6	32
80	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. <i>ACS Nano</i> , 2021, 15, 1186-1198.	14.6	32
81	A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2013, 119, 766-773.	4.1	31
82	Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1063-1070.	7.0	31
83	Prognostic value of <sup>18</sup> F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma. <i>Journal of Radiation Oncology</i> , 2013, 2, 27-34.	0.7	30
84	Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study. <i>NMR in Biomedicine</i> , 2014, 27, 681-691.	2.8	26
85	FDG uptake in colonic villous adenomas. <i>Annals of Nuclear Medicine</i> , 2005, 19, 331-334.	2.2	25
86	PET Radiotracers for Imaging the Proliferative Status of Solid Tumors. <i>PET Clinics</i> , 2009, 4, 1-15.	3.0	23
87	PET/MRI for the body imager: abdominal and pelvic oncologic applications. <i>Abdominal Imaging</i> , 2015, 40, 1387-1404.	2.0	23
88	Measurement Repeatability of <sup>18</sup> F-FDG PET/CT Versus <sup>18</sup> F-FDG PET/MRI in Solid Tumors of the Pelvis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1080-1086.	5.0	23
89	Positron Emission Tomography with [ <sup>18</sup> F]-3-Deoxy-3-fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: a Pilot Study. <i>Molecular Imaging and Biology</i> , 2013, 15, 106-113.	2.6	22
90	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. <i>Lancet Oncology</i> , The, 2018, 19, 1082-1093.	10.7	21

#	ARTICLE	IF	CITATIONS
91	Repeatability of Quantitative Brown Adipose Tissue Imaging Metrics on Positron Emission Tomography with 18F-Fluorodeoxyglucose in Humans. <i>Cell Metabolism</i> , 2019, 30, 212-224.e4.	16.2	21
92	[ 18 F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. <i>Molecular Therapy</i> , 2015, 23, 1110-1122.	8.2	18
93	The Emerging Role of PET/MR Imaging in Gynecologic Cancers. <i>PET Clinics</i> , 2016, 11, 425-440.	3.0	18
94	Molecular Imaging for Radiotherapy Planning and Response Assessment for Cervical Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 493-500.	4.6	15
95	Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4245-4255.	7.0	15
96	Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8th edition staging. <i>Head and Neck</i> , 2018, 40, 2280-2287.	2.0	14
97	Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa. <i>Case Reports in Oncology</i> , 2020, 13, 911-915.	0.7	14
98	A prospective trial comparing FDG PET / CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2014, 3, 1493-1501.	2.8	13
99	Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL). <i>Blood</i> , 2008, 112, 371-371.	1.4	13
100	Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. <i>Radiotherapy and Oncology</i> , 2017, 122, 445-451.	0.6	12
101	First-in-Man Evaluation of <sup>124</sup> I-PGN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment. <i>Molecular Imaging</i> , 2017, 16, 153601211773334.	1.4	12
102	Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. <i>Oncotarget</i> , 2017, 8, 104303-104314.	1.8	12
103	Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. <i>Theranostics</i> , 2021, 11, 9721-9737.	10.0	12
104	Imaging Tumor Phenotype: 1 Plus 1 Is More Than 2. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1567-1569.	5.0	11
105	Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer. <i>EJNMMI Research</i> , 2018, 8, 52.	2.5	11
106	Suicide genes: monitoring cells in patients with a safety switch. <i>Frontiers in Pharmacology</i> , 2014, 5, 241.	3.5	10
107	Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy?. <i>Journal of Dermatology</i> , 2021, 48, e80-e81.	1.2	10
108	Coronary circulatory function with increasing obesity: A complex U-turn. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13755.	3.4	10

#	ARTICLE	IF	CITATIONS
109	Evaluation of breast and gynecologic cancers by positron emission tomography. <i>Seminars in Roentgenology</i> , 2002, 37, 151-168.	0.6	9
110	Indeterminate Findings on Oncologic PET/CT: What Difference Does PET/MRI Make?. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 292-299.	1.0	9
111	Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward. <i>Blood Reviews</i> , 2016, 30, 389-399.	5.7	9
112	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2017, 11, 338-345.	2.6	9
113	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with <sup>18</sup> F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354.	2.5	8
114	Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by 18F-FDG PET/CT: a Case Report and Review of Literature. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 1-6.	1.0	7
115	Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 483-487.	2.0	6
116	The role of positron emission tomography for non-small cell lung cancer. <i>Practical Radiation Oncology</i> , 2011, 1, 282-288.	2.1	6
117	A Role of PET Agents Beyond FDG in Gynecology. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 501-511.	4.6	6
118	PET Imaging for Gynecologic Malignancies. <i>Radiologic Clinics of North America</i> , 2021, 59, 813-833.	1.8	6
119	Percutaneous Minimally Invasive Thermal Ablation of Musculoskeletal Lesions. <i>PET Clinics</i> , 2018, 13, 579-585.	3.0	4
120	Radiologic Assessment of Groin Lymph Nodes in Pelvic Malignancies. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 947-953.	2.5	4
121	A Projection-Domain Low-Count Quantitative SPECT Method for <sup>18</sup> F-Particle-Emitting Radiopharmaceutical Therapy. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2023, 7, 62-74.	3.7	4
122	Clinical-pathologic conference in general thoracic surgery: Cardiac lymphoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 130, 870-874.	0.8	3
123	Detection of additional primary neoplasms on 18F-Fluciclovine PET/CT in patients with primary prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262647.	5.0	3
124	Pilot Study: PARP1 Imaging in Advanced Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2022, 24, 853-861.	2.6	3
125	Diffuse Muscle Uptake of Technetium-99M MDP in a Patient with Lung Cancer. <i>Clinical Nuclear Medicine</i> , 1988, 13, 538-540.	1.3	2
126	<sup>18</sup> F-FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol. <i>Journal of Nuclear Medicine</i> , 2022, 63, 602-608.	5.0	2



#	ARTICLE	IF	CITATIONS
127	False-Negative Radionuclide Cisternography in Massive Communicating Hydrocephalus: Value of the Vertex View and CT Correlation. <i>Clinical Nuclear Medicine</i> , 1989, 14, 819-822.	1.3	1
128	Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience. <i>Blood</i> , 2016, 128, 5611-5611.	1.4	1
129	Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in high risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5524-5524.	1.6	1
130	Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma. <i>Rare Tumors</i> , 2021, 13, 203636132110524.	0.6	1
131	<sup>18</sup> F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy—Results from Multicenter ACRIN 6685 Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1887-1890.	5.0	1
132	Scintigraphic Demonstration of a Large Communicating Posterior Fossa Cyst. <i>Clinical Nuclear Medicine</i> , 1989, 14, 627-628.	1.3	0
133	Surveillance FDG-PET Detection of Asymptomatic Recurrences in Patients. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 457-458.	0.4	0
134	Response to the Letter to the Editor Regarding the Manuscript Entitled “Positron Emission Tomography with [18F]-3-Deoxy-3-Fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: A Pilot Study”. <i>Molecular Imaging and Biology</i> , 2013, 15, 786-787.	2.6	0
135	Clinical application of PET/MRI in oncology. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, spcone-spcone.	3.4	0
136	A2-05: Prognostic value of positron emission tomography in resected stage I non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S314.	1.1	0
137	A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 553-553.	1.6	0
138	Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5585-5585.	1.6	0
139	An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 286-293.	1.3	0